Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Appropriately aggregate holistic technologies via accurate expertise. Intrinsicly strategize worldwide initiatives and premium methodologies.

Parallel Induction of CH505 B Cell Ontogeny-Guided Neutralizing Antibodies and tHIVconsvX Conserved Mosaic-Specific T Cells against HIV-1.

Wee EG. et al, (2019), Molecular therapy. Methods & clinical development, 14, 148 - 160

Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study).

Mothe B. et al, (2019), EClinicalMedicine, 11, 65 - 80

Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA

Moyo N. et al, (2019), Molecular Therapy - Methods & Clinical Development, 12, 32 - 46

Complete protection of the BALB/c and C57BL/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine.

Rahim MN. et al, (2019), PLoS pathogens, 15

Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Kilpeläinen A. et al, (2019), Frontiers in immunology, 10

Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1

Borthwick NJ. et al, (2018), PLOS ONE, 13, e0197299 - e0197299

HIV-1-neutralizing antibody induced by simian adenovirus- and poxvirus MVA-vectored BG505 native-like envelope trimers

Capucci S. et al, (2017), PLOS ONE, 12, e0181886 - e0181886

Long-term follow up of human T-cell responses to conserved HIV-1 regions elicited by DNA/simian adenovirus/MVA vaccine regimens

Moyo N. et al, (2017), PLOS ONE, 12, e0181382 - e0181382

HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells

Wee EG. et al, (2017), Molecular Therapy, 25, 494 - 503

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection

Ondondo B. et al, (2016), Molecular Therapy, 24, 832 - 842

APOBEC3G-Induced Hypermutation of Human Immunodeficiency Virus Type-1 Is Typically a Discrete “All or Nothing” Phenomenon

Armitage AE. et al, (2012), PLoS Genetics, 8, e1002550 - e1002550

Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

Tenzer S. et al, (2009), Nature Immunology, 10, 636 - 646

P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance

Tenzer S. et al, (2009), Retrovirology, 6, P252 - P252

Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants

Slyker JA. et al, (2005), Vaccine, 23, 4711 - 4719

A Rab-E GTPase Mutant Acts Downstream of the Rab-D Subclass in Biosynthetic Membrane Traffic to the Plasma Membrane in Tobacco Leaf Epidermis

Zheng H. et al, (2005), The Plant Cell, 17, 2020 - 2036

Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa

Nkolola JP. et al, (2004), Gene Therapy, 11, 1068 - 1080

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans

Mwau M. et al, (2004), Journal of General Virology, 85, 911 - 919

Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine

Hanke T. et al, (2003), Journal of General Virology, 84, 361 - 368

Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic human immunodeficiency virus type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost

Vinner L. et al, (2003), Journal of General Virology, 84, 203 - 213

Development of a DNA-MVA/HIVA vaccine for Kenya

Hanke T. et al, (2002), Vaccine, 20, 1995 - 1998

Load More

Include forthcoming?